Efficacy of cetuximab in locally advanced or metastatic adenoid cystic carcinoma. Phase II.

Status

Not yet recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2006-001694-23-HU

Enrollment

Registered

2006-05-22

Start date

2006-08-21

Completion date

Unknown

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Investigating the efficacy of cetuximab (Erbitux) in locally advanced or metastatic adenoid cystic carcinoma expressing EGFR.

Interventions

Trade Name: Erbitux Product Name: Erbitux Product Code: C225 Pharmaceutical Form: Solution for infusion

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: age:18-80 year signed informed concent histologically proven adenoid cystic carcinoma EGFR pozitivity overall performance status:ECOG:0-2. suitible cardiac, renal and hepatic function Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: bed performance status: ECOG:3-4 heart failure (NYHA 2-4), major cardiac arrhytmia creatinin more than 2x UNL, ALT or AST more 5x UNL

Design outcomes

Primary

Measure	Time frame
Main Objective: To evalute the efficacy of adding cetuximab to standard treatment of adenoid cystic carcinoma. ;Secondary Objective: ;Primary end point(s): Time to progression, clinical response rate	—

Countries

Hungary

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026